United Therapeutics CFO exercises options, sells 10K shares
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share, then sold 10,000 shares in multiple open-market trades on the same day under a Rule 10b5-1 trading plan. Following these transactions, he holds 18,876 shares of common stock directly.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($4.32M approx. pre-tax spread)
Exercise and Sale
11 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.49M)
Approx. gross sale proceeds
$5.49M
Approx. exercise cost
$1.18M
Approx. pre-tax spread
$4.32M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $117.76 | $1.18M |
| Sale | Common Stock | 46 | $542.9374 | $25K |
| Sale | Common Stock | 154 | $544.369 | $84K |
| Sale | Common Stock | 442 | $545.1386 | $241K |
| Sale | Common Stock | 134 | $547.0788 | $73K |
| Sale | Common Stock | 2,037 | $548.0179 | $1.12M |
| Sale | Common Stock | 1,974 | $549.1055 | $1.08M |
| Sale | Common Stock | 3,333 | $550.0399 | $1.83M |
| Sale | Common Stock | 1,560 | $551.0977 | $860K |
| Sale | Common Stock | 320 | $551.825 | $177K |
Holdings After Transaction:
Stock Option — 10,000 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (10)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $551.62 to $552.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $542.02 to $543.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $543.76 to $544.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $544.80 to $545.67. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $546.60 to $547.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $547.60 to $548.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $548.60 to $549.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $549.61 to $550.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $550.62 to $551.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Options exercised: 10,000 shares
Exercise price: $117.76 per share
+4 more
7 metrics
Shares sold
10,000 shares
Total common shares sold in open-market transactions on 2026-06-11
Options exercised
10,000 shares
Common shares acquired via stock option exercise on 2026-06-11
Exercise price
$117.76 per share
Exercise price of stock option for 10,000 underlying common shares
Post-transaction holdings
18,876 shares
Common shares directly owned by CFO after reported trades
Largest reported sale price
$551.8250 per share
Highest individual weighted average price among reported sale tranches
Smallest reported sale price
$542.9374 per share
Lowest individual weighted average price among reported sale tranches
Option expiration date
March 15, 2027
Scheduled expiration date of the exercised stock option grant
Key Terms
Rule 10b5-1 trading plan, stock options, derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did UNITED THERAPEUTICS (UTHR) report for CFO James Edgemond?
UNITED THERAPEUTICS reported that CFO James Edgemond exercised stock options for 10,000 common shares and sold 10,000 shares in open-market transactions. All trades occurred on the same day and were disclosed in a Form 4 insider trading report.
What stock options did the UNITED THERAPEUTICS (UTHR) CFO exercise in this Form 4?
James Edgemond exercised stock options covering 10,000 shares of UNITED THERAPEUTICS common stock. The options had a stated exercise price of $117.76 per share and were originally scheduled to expire on March 15, 2027, according to the Form 4 transaction data.
Were the UNITED THERAPEUTICS (UTHR) CFO’s trades made under a Rule 10b5-1 plan?
Yes. A footnote states the option exercise and subsequent share sales were executed under a Rule 10b5-1 trading plan that James Edgemond entered into on October 31, 2025. Such plans pre-schedule trades to occur automatically under defined conditions.
Did the UNITED THERAPEUTICS (UTHR) Form 4 include any remaining stock options for the CFO?
The Form 4 shows a stock option for 10,000 shares that was exercised into common stock, with 10,000 underlying shares delivered. The derivative summary lists no remaining derivative positions, indicating this particular option grant was fully exercised in the reported transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
